The Risk of Venous Thromboembolism and Ischemic Stroke Stratified by VTE Risk Following Multiple Myeloma: A Korean Population-Based Cohort Study

被引:0
|
作者
Han, Hyun Jin [1 ,2 ]
Kim, Miryoung [2 ,3 ]
Lee, Jiyeon [1 ,2 ]
Suh, Hae Sun [1 ,2 ,4 ]
机构
[1] Kyung Hee Univ, Grad Sch, Dept Regulatory Sci, Seoul 02447, South Korea
[2] Kyung Hee Univ, Inst Regulatory Innovat Sci, Seoul 02447, South Korea
[3] Pusan Natl Univ, Coll Pharm, Busan 46241, South Korea
[4] Kyung Hee Univ, Coll Pharm, Seoul 02447, South Korea
关键词
venous thromboembolism; ischemic stroke; multiple myeloma; IMPEDE VTE; THROMBOSIS; VALIDATION;
D O I
10.3390/jcm13102829
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Multiple myeloma (MM) is associated with high morbidity and mortality, with elevated rates of arterial thrombosis and venous thromboembolism (VTE) and ischemic stroke (IS). We aimed to estimate the incidence of VTE and IS categorized by the VTE risk grade among individuals with MM in Korea. Additionally, we explored the potential of the IMPEDE VTE score as a tool for assessing IS risk in patients with MM. Methods: This retrospective cohort study comprised 37,168 individuals aged >= 18 years newly diagnosed with MM between January 2008 and December 2021 using the representative claims database of the Korean population. The risk of the incidence of VTE and IS within 6 months after MM diagnosis was stratified based on high-risk (IMPEDE VTE score >= 8) and low-risk (<8) categories. The hazard ratios (HRs) were estimated using Cox proportional hazard models. Results: The VTE incidence was 120.4 per 1000 person-years and IS incidence was 149.3 per 1000 person-years. Statistically significant differences were observed in the cumulative incidence rates of VTE between groups with high and low VTE scores (p < 0.001) and between individuals aged <= 65 years (p < 0.001) and those with a Charlson comorbidity index (CCI) >= 3 compared to lower scores (p < 0.001). Additionally, the cumulative incidence rate of IS differed significantly across all groups (p < 0.001). The HR for the high-risk group in VTE and IS occurrence was 1.59 (95% CI, 1.26-2.00) and 3.47 (95% CI, 2.99-4.02), respectively. Conclusions: It is important to screen and manage high-risk groups for the early development of VTE or IS in patients with newly diagnosed MM.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Initiation of statins and risk of venous thromboembolism: Population-based matched cohort study
    Skajaa, Nils
    Szepligeti, Szimonetta K.
    Horvath-Puho, Erzsebet
    Ghanima, Waleed
    Hansen, John-Bjarne
    Sorensen, Henrik Toft
    THROMBOSIS RESEARCH, 2019, 184 : 99 - 104
  • [22] Risk of Stroke in Patients with Multiple Myeloma: A Nationwide Population-Based Study
    Liu, Chia-Jen
    Liu, Yao-Chung
    Hong, Ying-Chung
    Ku, Fan-Chen
    Gau, Jyh-Pyng
    Chiou, Tzeon-Jye
    Tzeng, Cheng-Hwai
    BLOOD, 2014, 124 (21)
  • [23] INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) AFTER BARIATRIC SURGERY: A POPULATION-BASED COHORT STUDY
    Froehling, David A.
    Daniels, Paul
    Mauck, Karen F.
    Litin, Scott
    Collazo-Clavell, Maria L.
    Petterson, Tanya M.
    Sarr, Michael G.
    Heit, John A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2012, 27 : S227 - S228
  • [24] Hormone therapy in postmenopausal women associated with risk of stroke and venous thromboembolism: a population-based cohort study in Taiwan
    Chang, Wei-Chuan
    Wang, Jen-Hung
    Ding, Dah-Ching
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (02): : 197 - 202
  • [25] Incidence of Cancer-Associated Venous Thromboembolism (VTE): A Population-Based Cohort Study
    Ashrani, Aneel A.
    Heit, John A.
    Crusan, Daniel J.
    Petterson, Tanya M.
    Bailey, Kent R.
    Melton, L. Joseph, III
    BLOOD, 2008, 112 (11) : 1306 - 1306
  • [26] Risk of developing Venous Thromboembolism in Multiple Myeloma; Based on current VTE risk assessment models : Impede VTE Score & IMWG guidelines
    Martinez Alfonzo, Ines
    Askari, Elham
    Velasco Rodriguez, Diego
    Gallego Lopez, Jorge
    Alonso Dominguez, Juan Manuel
    Serrano Lopez, Juana
    Lopez Perez, Miriam
    Franganillo Suarez, Aida
    Vidal Laso, Rosa
    Prieto Pareja, Elena
    Arquero Portero, Teresa
    Cordoba Mascunano, Raul
    Llamas, Pilar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E196 - E196
  • [27] Novel risk factors for venous thromboembolism (VTE): A population-based case-control study.
    Heit, JA
    Farmer, SA
    Petterson, TM
    Bailey, KR
    Melton, LJ
    BLOOD, 2005, 106 (11) : 463A - 463A
  • [28] The risk of venous thromboembolism (VTE) among cancer patients by tumor site: A population-based study.
    Heit, JA
    Petterson, TM
    Marks, RS
    Bailey, KR
    Melton, LJ
    BLOOD, 2004, 104 (11) : 711A - 711A
  • [29] VENOUS THROMBOEMBOLISM (VTE) IN COLON CANCER: A POPULATION-BASED COHORT STUDY OF VTE RATES FOLLOWING SURGERY AND DURING ADJUVANT CHEMOTHERAPY.
    Patel, S. V.
    Zhang, L.
    Wei, S.
    Merchant, S.
    Nanji, S.
    James, P. D.
    Booth, C. M.
    DISEASES OF THE COLON & RECTUM, 2019, 62 (06) : E79 - E79
  • [30] Incidence and Risk Factors of Venous Thromboembolism Following Hepatectomy for Colorectal Metastases: A Population-Based Retrospective Cohort Study
    Hanna, Nader
    Brogly, Susan B.
    Wei, Xuejiao Shelly
    Booth, Christopher M.
    Nanji, Sulaiman
    WORLD JOURNAL OF SURGERY, 2022, 46 (01) : 180 - 188